The current Covid-19 pandemic is the greatest challenge to our society in a generation. If we do nothing, its consequences will be devastating. There is an ethical obligation for any organisation in a position to help to do so. At e-therapeutics we have a technology platform that is capable of being deployed to carry out rapid in silico phenotypic screening. We have successfully leverages this to find active compounds capable of protecting human cells in influenza. We believe that the same strategies employed in our work on influenza could be used to identify combinations of compounds with useful activity against Sars-CoV-2, the virus which causes Covid-19. We require the help of established partners with relevant assays for Sars-CoV-2. Click below to download a summary of our Influenza project:

Download our COVID-19 NDD overview here